Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Kerry Keertikar"'
Autor:
Ying Zhai, De-Yi Yang, Ernest Asante-Appiah, Lei Chen, Haiqun Tang, Paul Ingravallo, Amin A. Nomeir, John P. Caldwell, Ling Tong, Guowei Zhou, Wensheng Yu, Yueheng Jiang, Oleg Selyutin, Anilkumar G. Nair, Seong Heon Kim, Rong Liu, Joseph A. Kozlowski, Qingbei Zeng, Stuart B. Rosenblum, Michael P. Dwyer, Rong Kong, Ellen Xia, Sony Agrawal, Robert Mazzola, Bandarpalle B. Shankar, Kerry Keertikar
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 28:1954-1957
HCV NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays thus making them attractive components for inclusion in an all oral fixed dose combination regimen. Herein, we describe the discovery and characterization of s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd2480c8ed858188f3382243eccdd83
https://doi.org/10.1016/j.bmcl.2018.03.049
https://doi.org/10.1016/j.bmcl.2018.03.049
Autor:
Kerry Keertikar, Marc A. Labroli, Randall R. Rossman, Timothy J. Guzi, Michael P. Dwyer, Cory Poker
Publikováno v:
Tetrahedron Letters. 57:2601-2603
This Letter describes the development of a convergent, efficient route to the CHK1 inhibitor MK-8776. This synthetic approach relies upon the cyclization of a bispyrazole adduct 10 with a optically pure β-keto nitrile 9 to construct the pyrazolo[1,5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12f489537296ff2339e56f3d6b49ed86
https://doi.org/10.1016/j.tetlet.2016.04.102
https://doi.org/10.1016/j.tetlet.2016.04.102
Autor:
Guowei Zhou, Ling Tong, Bandarpalle B. Shankar, De-Yi Yang, Rong Liu, Sony Agrawal, Ying Zhai, Rong Kong, Craig A. Coburn, Lei Chen, Qingbei Zeng, Seong Heon Kim, Brian J. Lavey, Kerry Keertikar, Razia Rizvi, Ellen Xia, Michael Wong, Yueheng Jiang, Stuart B. Rosenblum, Wensheng Yu, Ernest Asante-Appiah, Anilkumar G. Nair, Joseph A. Kozlowski, Paul Ingravallo, Amin A. Nomeir, Michael P. Dwyer, Oleg Selyutin
Publikováno v:
Bioorganicmedicinal chemistry letters. 26(16)
A matched and mixed capping SAR study was conducted on the tetracyclic indole class of HCV NS5A inhibitors to examine the influence of modifications of this region on the overall HCV virologic resistance profiles.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95943f585472c6925fcc6867075afb6
https://pubmed.ncbi.nlm.nih.gov/27423481
https://pubmed.ncbi.nlm.nih.gov/27423481
Autor:
Jocelyn Rivera, Xiaoying Xu, Haengsoon Park, Lesley Schultz, Kamil Paruch, David A. Parry, Alvarez Carmen S, Emma Lees, Thierry O. Fischmann, Doll Ronald J, Tara M. Stauffer, Laura R. Rokosz, Chad E. Knutson, Wolfgang Seghezzi, Vincent S. Madison, Alan Hruza, Michael P. Dwyer, Ray Anthony James, Derek Wiswell, Mckittrick Brian A, Greg Tucker, Frances Shanahan, Nicole Sgambellone, Kerry Keertikar, Randall R. Rossman, Timothy J. Guzi, Vidyadhar M. Paradkar, Yaolin Wang, Quiao Zhou, Paul Kirschmeier, Amin A. Nomeir, Tin-Yau Chan, Courtney Brown
Publikováno v:
ACS Medicinal Chemistry Letters. 1:204-208
Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b7390edd40f7ca65dc0aeccd13f3ca9
https://doi.org/10.1021/ml100051d
https://doi.org/10.1021/ml100051d
Autor:
Ying Zhai, Ellen Xia, Lei Chen, Bandarpalle B. Shankar, Qingbei Zeng, Anilkumar G. Nair, Sony Agrawal, Ronald N. Buckle, Guowei Zhou, Kannan P. Naicker, John P. Caldwell, Ling Tong, Yueheng Jiang, Stuart B. Rosenblum, Wensheng Yu, Kerry Keertikar, Haiqun Tang, Seong Heon Kim, Rong Liu, De-Yi Yang, Paul Ingravallo, Gregory Scott Martin, Samuel A. Vellekoop, Melissa L. Allard, Christian L. Holst, Michael P. Dwyer, Amin A. Nomeir, Robert Mazzola, Polivina Jolicia F Gauuan, Joseph A. Kozlowski, Oleg Selyutin, Rong Kong
Publikováno v:
Bioorganicmedicinal chemistry letters. 26(5)
HCV NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays thus making them attractive components for inclusion in an all oral fixed dose combination treatment regimen. Herein we describe the research efforts that led
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85586f1ce259c9e4c3146d6078489ecd
https://pubmed.ncbi.nlm.nih.gov/26850003
https://pubmed.ncbi.nlm.nih.gov/26850003
Autor:
Peter J. Barelli, Spencer R. Bates, Edith J. Banner, Nakul Telang, Kayleigh E. Hall, Rebecca Osterman, Kara L. Finzel, Xin Jia, Lauren T. Firich, R. Scott Welden, Matthew B. Coppock, John T. Gupton, John A. Stafford, Eric F. Worrall, Emily J. Kluball, James E. Eaton, Benjamin C. Giglio, Kerry Keertikar, Rene P.F. Kanters
Studies directed at the synthesis of (Z)-5-benzylidene-4-arylpyrrol-2(5H)-ones from (Z)-3-aryl-3-haloenoic acids are described. The successful strategy relies on the preparation of (Z)-3-aryl-3-haloenoic acids from acetophenones through the correspon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d528eea90de2115065c63b0408e9b66
https://europepmc.org/articles/PMC2997076/
https://europepmc.org/articles/PMC2997076/
Autor:
Marc A. Labroli, Alvarez Carmen S, Randall R. Rossman, Cory Poker, Nicole Davis, Wolfgang Seghezzi, Jose S. Duca, Vincent S. Madison, David A. Parry, Derek Wiswell, Michael P. Dwyer, Timothy J. Guzi, Kamil Paruch, Thierry O. Fischmann, Kerry Keertikar
Publikováno v:
Bioorganicmedicinal chemistry letters. 21(1)
Previous efforts by our group have established pyrazolo[1,5-a]pyrimidine as a viable core for the development of potent and selective CDK inhibitors. As part of an effort to utilize the pyrazolo[1,5-a]pyrimidine core as a template for the design and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a154595935eac36ad0672ecec228c2a
https://pubmed.ncbi.nlm.nih.gov/21094607
https://pubmed.ncbi.nlm.nih.gov/21094607
Autor:
Kamil Paruch, Jose S. Duca, Wolfgang Seghezzi, David A. Parry, Frances Shanahan, Kerry Keertikar, Emma Lees, Carmen S. Alvarez, Doll Ronald J, Timothy J. Guzi, Thierry O. Fischmann, Michael P. Dwyer, Alan Hruza, Nicole Sgambellone, Derek Wiswell, Vincent Madison
Publikováno v:
Bioorganicmedicinal chemistry letters. 17(22)
A series of four bicyclic cores were prepared and evaluated as cyclin-dependent kinase-2 (CDK2) inhibitors. From the in-vitro and cell-based analysis, the pyrazolo[1,5-a]pyrimidine core (represented by 9) emerged as the superior core for further elab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1fb0ddeade0a1d1047966807e775062
https://pubmed.ncbi.nlm.nih.gov/17904366
https://pubmed.ncbi.nlm.nih.gov/17904366